ALT-P7 (HM2-MMAE)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Breast Cancer
Conditions
HER2-positive Breast Cancer
Trial Timeline
Jan 11, 2018 → Jan 15, 2021
NCT ID
NCT03281824About ALT-P7 (HM2-MMAE)
ALT-P7 (HM2-MMAE) is a phase 1 stage product being developed by Alteogen for HER2-positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03281824. Target conditions include HER2-positive Breast Cancer.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive Breast Cancer were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03281824 | Phase 1 | Completed |
Competing Products
20 competing products in HER2-positive Breast Cancer